Open Access

A promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells

  • Authors:
    • Ivan Delgado‑Enciso
    • Juan Paz‑Garcia
    • Alejandrina Rodriguez‑Hernandez
    • Violeta M. Madrigal‑Perez
    • Ariana Cabrera‑Licona
    • Alejandro Garcia‑Rivera
    • Alejandro D. Soriano‑Hernandez
    • Jose L. Cortes‑Bazan
    • Hector R. Galvan‑Salazar
    • Jose Valtierra‑Alvarez
    • Jose Guzman‑Esquivel
    • Iram P. Rodriguez‑Sanchez
    • Margarita L. Martinez‑Fierro
    • Brenda Paz‑Michel
  • View Affiliations

  • Published online on: December 20, 2017     https://doi.org/10.3892/mmr.2017.8336
  • Pages: 3503-3510
  • Copyright: © Delgado‑Enciso et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteoarthritis (OA) is a chronic disorder of synovial joints, in which there is progressive softening and disintegration of the articular cartilage. OA is the most common form of arthritis, and is the primary cause of disability and impaired quality of life in the elderly. Despite considerable medical necessity, no treatment has yet been proven to act as a disease‑modifying agent that may halt or reverse the structural progression of OA. The replacement of the joint with a prosthesis appears to be the best option in the advanced stages of the disease. A formulation (BIOF2) for cartilage regeneration has been recently developed. The present study evaluated the effects of BIOF2 on gene expression in human cell cultures, followed by efficacy trials in three OA animal models. Human synovial fluid cells that were exposed to the formulation exhibited increased transcription factor SOX‑9 (SOX9; chondrogenic factor) expression, and decreased mimecan (mineralization inducer) and macrophage‑stimulating protein receptor (osteoclastogenic factor) expression. The intra‑articular application of BIOF2 in the animal models significantly increased cartilage thickness from 12 to 31% at 28 days, compared with articular cartilage treated with saline solution. The articular area and number of chondrocytes additionally increased significantly, maintaining an unaltered chondrocyte/mm2 proportion. Evaluation of the histological architecture additionally displayed a decrease in the grade of articular damage in the groups treated with BIOF2. In conclusion, BIOF2 has proven to be effective for treating OA in animal models, most likely due to SOX9 overexpression in articular cells.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 17 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Delgado‑Enciso I, Paz‑Garcia J, Rodriguez‑Hernandez A, Madrigal‑Perez VM, Cabrera‑Licona A, Garcia‑Rivera A, Soriano‑Hernandez AD, Cortes‑Bazan JL, Galvan‑Salazar HR, Valtierra‑Alvarez J, Valtierra‑Alvarez J, et al: A promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells. Mol Med Rep 17: 3503-3510, 2018
APA
Delgado‑Enciso, I., Paz‑Garcia, J., Rodriguez‑Hernandez, A., Madrigal‑Perez, V.M., Cabrera‑Licona, A., Garcia‑Rivera, A. ... Paz‑Michel, B. (2018). A promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells. Molecular Medicine Reports, 17, 3503-3510. https://doi.org/10.3892/mmr.2017.8336
MLA
Delgado‑Enciso, I., Paz‑Garcia, J., Rodriguez‑Hernandez, A., Madrigal‑Perez, V. M., Cabrera‑Licona, A., Garcia‑Rivera, A., Soriano‑Hernandez, A. D., Cortes‑Bazan, J. L., Galvan‑Salazar, H. R., Valtierra‑Alvarez, J., Guzman‑Esquivel, J., Rodriguez‑Sanchez, I. P., Martinez‑Fierro, M. L., Paz‑Michel, B."A promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells". Molecular Medicine Reports 17.3 (2018): 3503-3510.
Chicago
Delgado‑Enciso, I., Paz‑Garcia, J., Rodriguez‑Hernandez, A., Madrigal‑Perez, V. M., Cabrera‑Licona, A., Garcia‑Rivera, A., Soriano‑Hernandez, A. D., Cortes‑Bazan, J. L., Galvan‑Salazar, H. R., Valtierra‑Alvarez, J., Guzman‑Esquivel, J., Rodriguez‑Sanchez, I. P., Martinez‑Fierro, M. L., Paz‑Michel, B."A promising novel formulation for articular cartilage regeneration: Preclinical evaluation of a treatment that produces SOX9 overexpression in human synovial fluid cells". Molecular Medicine Reports 17, no. 3 (2018): 3503-3510. https://doi.org/10.3892/mmr.2017.8336